A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 212,600 shares of BDTX stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
212,600
Previous 450,400 52.8%
Holding current value
$1.02 Million
Previous $1.27 Million 14.85%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$2.67 - $5.74 $634,926 - $1.36 Million
-237,800 Reduced 52.8%
212,600 $1.08 Million
Q4 2023

Feb 13, 2024

BUY
$1.77 - $3.03 $215,055 - $368,145
121,500 Added 36.94%
450,400 $1.27 Million
Q3 2023

Nov 14, 2023

BUY
$2.87 - $4.99 $310,534 - $539,918
108,200 Added 49.03%
328,900 $944,000
Q2 2023

Aug 11, 2023

BUY
$1.43 - $6.18 $4,576 - $19,776
3,200 Added 1.47%
220,700 $1.12 Million
Q1 2023

May 12, 2023

SELL
$1.35 - $3.14 $4,202 - $9,774
-3,113 Reduced 1.41%
217,500 $411,000
Q4 2022

Feb 13, 2023

BUY
$1.28 - $2.51 $3,728 - $7,311
2,913 Added 1.34%
220,613 $397,000
Q3 2022

Nov 14, 2022

SELL
$1.96 - $4.01 $106,431 - $217,751
-54,302 Reduced 19.96%
217,700 $368,000
Q2 2022

Aug 12, 2022

BUY
$1.5 - $3.63 $11,266 - $27,264
7,511 Added 2.84%
272,002 $669,000
Q1 2022

May 13, 2022

SELL
$2.66 - $5.61 $321,617 - $678,299
-120,909 Reduced 31.37%
264,491 $733,000
Q4 2021

Feb 11, 2022

BUY
$5.18 - $8.48 $2 Million - $3.27 Million
385,400 New
385,400 $2.05 Million
Q2 2021

Aug 13, 2021

SELL
$12.19 - $28.17 $226,734 - $523,962
-18,600 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$22.23 - $34.75 $413,478 - $646,350
18,600 New
18,600 $451,000
Q3 2020

Nov 13, 2020

SELL
$26.17 - $43.07 $693,688 - $1.14 Million
-26,507 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$22.3 - $44.8 $591,106 - $1.19 Million
26,507 New
26,507 $1.12 Million

Others Institutions Holding BDTX

About Black Diamond Therapeutics, Inc.


  • Ticker BDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,339,500
  • Market Cap $174M
  • Description
  • Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...
More about BDTX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.